The increased risk of pneumonitis should be considered in future clinical trials evaluating the efficacy of the combination of anti-PD-1 or anti-PD-L1 therapy with radiotherapy in patients with thoracic malignancies, such as EC. Here, CD274 is linked to pneumonitis.